CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation

Clinica Chimica Acta

Volumn 467, Issue , 2017, Pages 27-33

  Kuhlmann, Julia ^a   Andreasson, Ulf ^b,c   Pannee, Josef ^b,c   Bjerke, Maria ^b,c   Portelius, Erik ^b,c   Leinenbach, Andreas ^d   Bittner, Tobias ^d   Korecka, Magdalena ^e   Jenkins, Rand G ^f   Vanderstichele, Hugo ^g   Stoops, Erik ^g   Lewczuk, Piotr ^h,i   Shaw, Leslie M ^e   Zegers, Ingrid ^a   Schimmel, Heinz ^a   Zetterberg, Henrik ^b,c,j   Blennow, Kaj ^b,c  

^a JOINT RESEARCH CENTRE   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Pharmaceutical Product Development   (United States)

^g ADX NEUROSCIENCES   (Belgium)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; A 1 42; Cerebrospinal fluid; Certified reference material; Reference measurement procedure

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CALIBRATION; ELECTROCHEMILUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SOLID PHASE EXTRACTION; STANDARDIZATION; TANDEM MASS SPECTROMETRY; CEREBROSPINAL FLUID; CLINICAL CHEMISTRY; STANDARD; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CLINICAL CHEMISTRY TESTS; HUMANS; PEPTIDE FRAGMENTS; REFERENCE STANDARDS;

EID: 85016990207     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.05.014     Document Type: Article

References (27)

1. [1] Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. Nat. Rev. Neurol. 6:3 (2010), 131–144.
2. [2] Strozyk, D., Blennow, K., White, L.R., Launer, L.J., CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:4 (2003), 652–656.
3. [3] Hampel, H., Frank, R., Broich, K., Teipel, S.J., Katz, R.G., Hardy, J., et al. Biomarkers for Alzheimer's disease: academic industry and regulatory perspectives. Nat. Rev. Drug Discov. 9:7 (2010), 560–574.
4. [4] Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5:3 (2006), 228–234.
5. [5] Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65:4 (2009), 403–413.
6. [6] Visser, P.J., Verhey, F., Knol, D.L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8:7 (2009), 619–627.
7. [7] Mattsson, N., Zetterberg, H., Hansson, O., et al. CSF biomarkers and incipient alzheimer disease in patients with mild cognitive impairment. J. Am. Med. Assoc. 302:4 (2009), 385–393.
8. [8] Blennow, K., Mattsson, N., Schöll, M., Hansson, O., Zetterberg, H., Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 36:5 (2015), 297–309.
9. [9] Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7:4 (2011), 386–395.
10. [10] Vanderstichele, H.M., Shaw, L.M., Vandijck, M., Jeromin, A., Zetterberg, H., Blennow, K., et al. Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin. Chem. 59:4 (2013), 710–712.
11. [11] Mattsson, N., Andreasson, U., Carrillo, M.C., Persson, S., Shaw, L.M., Zegers, I., et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. Biomark. Med 6:4 (2012), 401–407 2012/08/01.
12. [12] Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370:4 (2014), 311–321.
13. [13] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370:4 (2014), 322–333.
14. [14] ISO Guide 34, General requirements for the competence of reference material producers. Geneva 2009. 2009.
15. [15] Schimmel, H., Zegers, I., Performance criteria for reference measurement procedures and reference materials. Clin. Chem. Lab. Med. 53:6 (2015), 899–904.
16. [16] Zegers, I., Schimmel, H., To harmonize and standardize making measurement results comparable. Clin. Chem. 60:7 (2014), 911–913.
17. [17] Dillen, L., Cools, W., Vereyken, L., Timmerman, P., A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 3:1 (2011), 45–55.
18. [18] Lame, M.E., Chambers, E.E., Blatnik, M., Quantitation of amyloid beta peptides Ab1–38,Ab1–40, and Ab1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry. Anal. Biochem. 419:2 (2011), 133–139.
19. [19] Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J. Alzheimers Dis. 33:4 (2013), 1021–1032.
20. [20] Leinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andreasson, U., et al. Mass spectrometry–based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. Clin. Chem. 60:7 (2014), 987–994 2014 July 1.
21. [21] Korecka, M., Waligorska, T., Figurski, M., Toledo, J.B., Arnold, S.E., Grossman, M., et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-β42 in human cerebrospinal fluid using 2d uplc-tandem mass spectrometry. J. Alzheimers Dis. 41:2 (2014), 441–451 01/01/2014.
22. [22] Pannee, J., Gobom, J., Shaw, L.M., Korecka, M., Chambers, E.E., Lame, M., et al. Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement., 2015 in press.
23. [23] Broersen, K., Jonckheere, W., Rozenski, J., Vandersteen, A., Pauwels, K., Pastore, A., et al. A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease. Protein Eng. Des. Sel. 24:9 (2011), 743–750 2011 September 1.
24. [24] Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine. CLSI document C53-A. 2010, Clinical and Laboratory Standards Institute, Wayne, PA.
25. [25] Bjerke, M., Andreasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., et al. Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements. Clin. Chem. Lab. Med., 2015 in press.
26. [26] Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H., Anckarsäter, R., et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int. J. Alzheimers Dis., 2010, 2010, 11.
27. [27] Bittner, T., Zetterberg, H., Teunissen, C.E., Ostlund, R.E.J., Militello, M., Andreasson, U., et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid(1–42) in human cerebrospinal fluid. Alzheimers Dement., 2015 in press.